
    
      This is a prospective, open-label, single-arm, single-center study. There is no randomization
      or blinding. Subjects will receive the Intercept System procedure to treat one or two motion
      segments at L3/L4, L4/L5, or L5/S1 as identified by Modic Type 1 or 2 changes.
    
  